

Claire F Verschraegen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/738840/publications.pdf>

Version: 2024-02-01

185
papers

7,591
citations

66250

44
h-index

68831

81
g-index

190
all docs

190
docs citations

190
times ranked

9220
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	0.8	24
2	Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor. <i>Future Oncology</i> , 2022, 18, 1333-1342.	1.1	1
3	Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 318-320.	2.3	5
4	Low-Dose Enzalutamide in Metastatic Prostate Cancer—Longevity Over Conventional Survival Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e473-e484.	0.9	4
5	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. <i>Clinical Lung Cancer</i> , 2021, 22, e487-e497.	1.1	6
6	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. <i>Cell Research</i> , 2021, 31, 178-186.	5.7	146
7	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <i>Cancer</i> , 2021, 127, 938-945.	2.0	11
8	Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 122-125.	2.3	0
9	Benchmarks for Academic Oncology Faculty. <i>JCO Oncology Practice</i> , 2021, 17, e440-e444.	1.4	1
10	Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio. <i>Breast Cancer</i> , 2021, 28, 956-968.	1.3	5
11	Advances in epigenetic therapeutics with focus on solid tumors. <i>Clinical Epigenetics</i> , 2021, 13, 83.	1.8	53
12	Refractory dermatitis contributed by pityriasis versicolor: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 212.	0.4	2
13	Genomic features of rapid versus late relapse in triple negative breast cancer. <i>BMC Cancer</i> , 2021, 21, 568.	1.1	10
14	Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100158.	1.3	9
15	Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer. <i>BMC Cancer</i> , 2021, 21, 1177.	1.1	7
16	Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 27-34.	1.3	9
17	The mean absolute dose deviation—A common metric for the evaluation of dose-volume histograms in radiation therapy. <i>Medical Dosimetry</i> , 2020, 45, 186-189.	0.4	4
18	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. , 2020, 8, e001064.		16

#	ARTICLE	IF	CITATIONS
19	Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. <i>BMC Cancer</i> , 2020, 20, 383.	1.1	45
20	Low-Dose Enzalutamide in Late-Elderly Patients (≥ 75 Years Old) Presenting With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e660-e668.	0.9	14
21	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2541-2546.	1.2	93
22	Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour. <i>Annals of Oncology</i> , 2019, 30, v612-v613.	0.6	0
23	Country-Weighed Estimate of Prostate Cancer Hypofractionated Radiotherapy Toxicity Risk. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E469.	0.4	0
24	Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. <i>Cancer Cell</i> , 2019, 35, 428-440.e5.	7.7	571
25	Inhibition of the chimeric DnaJ ϵ PKAc enzyme by endogenous inhibitor proteins. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13783-13791.	1.2	7
26	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
27	Hypofractionated Nodal Irradiation for Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 13.	3.4	11
28	Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16548-e16548.	0.8	2
29	Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 94-94.	0.8	4
30	First real-world experience of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) since US FDA approval.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15691-e15691.	0.8	0
31	Low likelihood that potential germline findings identified during somatic tumor testing are evaluated: Room for improvement.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13037-e13037.	0.8	0
32	Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18201-e18201.	0.8	0
33	Abstract CT169: Pilot study testing the effects of BTK inhibitor ibrutinib and nivolumab on levels and function of myeloid-derived suppressor cells and other immune subsets in patients with metastatic solid tumors (NCT03525925)., 2019, , .		0
34	Axillary Lymph Node Involvement in Breast Cancer: A Random Walk Model of Tumor Burden. <i>Cureus</i> , 2019, 11, e6249.	0.2	3
35	Novel organometallic chloroquine derivative inhibits tumor growth. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5921-5933.	1.2	14
36	Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e149-e151.	0.4	19

#	ARTICLE	IF	CITATIONS
37	Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.. Journal of Clinical Oncology, 2018, 36, 2584-2584.	0.8	2
38	Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor.. Journal of Clinical Oncology, 2018, 36, 8563-8563.	0.8	4
39	Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2018, 36, 166-166.	0.8	5
40	NKTR-214. PEGylated engineered interleukin-2 (IL-2), CD122-biased immunostimulatory cytokine, Cancer immunotherapy. Drugs of the Future, 2018, 43, 0323.	0.0	0
41	Hypofractionated radiation therapy for early breast cancer and regional nodal irradiationâ€”the jury is still out. Translational Cancer Research, 2018, 7, S584-S586.	0.4	0
42	Two Phase 1 dose-escalation studies exploring multiple regimens of ltronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 315-326.	1.1	25
43	Breast cancer screening in patients with cancers other than breast. Breast Cancer Research and Treatment, 2017, 163, 343-348.	1.1	1
44	When Clinical Trial Participation Is Not an Option in the Era of Personalized Medicine: The Case of Two Patients. Oncology, 2017, 92, 55-60.	0.9	4
45	Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer. Annals of Oncology, 2017, 28, v123.	0.6	1
46	Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology, 2017, 35, 9086-9086.	0.8	11
47	Preoperative [18]fluorodeoxyglucose-positron emission tomography/computed tomography in early stage breast cancer: Rates of distant metastases. World Journal of Radiology, 2017, 9, 312.	0.5	2
48	Breast cancer screening in patients with cancers other than breast.. Journal of Clinical Oncology, 2017, 35, e13095-e13095.	0.8	0
49	Reply to M.C. Chamberlain and T.J. Kruser. Journal of Clinical Oncology, 2016, 34, 1827-1828.	0.8	3
50	Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Supportive Care in Cancer, 2016, 24, 3085-3093.	1.0	26
51	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 8503-8503.	0.8	43
52	Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 9036-9036.	0.8	21
53	Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. Journal of Thrombosis and Haemostasis, 2015, 13, 998-1003.	1.9	61
54	Urothelial Superior Vena Cava Syndrome with Limited Response to Radiation Therapy. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	0

#	ARTICLE	IF	CITATIONS
55	A first in human, dose escalation trial of MSC2363318A – a dual p70S6K/Akt inhibitor, for patients with advanced malignancies. <i>Annals of Oncology</i> , 2015, 26, ii25.	0.6	2
56	Successful Treatment of Non–Small Cell Lung Cancer With Erlotinib Throughout Pregnancy. <i>JAMA Oncology</i> , 2015, 1, 838.	3.4	19
57	Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. <i>Journal of Clinical Oncology</i> , 2015, 33, 4093-4098.	0.8	120
58	The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers. <i>Seminars in Oncology</i> , 2015, 42, 731-739.	0.8	17
59	SWOG S9005: Double blind phase III randomized trial of the anti-progestin agent mifepristone in the treatment of unresectable meningioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17084-e17084.	0.8	1
60	Choosing wisely: The utility and costs of routine staging imaging in breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17800-e17800.	0.8	4
61	Clinical Approach to Advanced Melanoma for Today and Tomorrow. , 2015, , 637-662.		0
62	Epigenetic Landscape of Acute Myelogenous Leukemia–Moving Toward Personalized Medicine. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 1669-1672.	1.2	6
63	Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 25-29.	0.5	12
64	A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers. <i>Translational Oncology</i> , 2014, 7, 349-354.	1.7	25
65	Methylation, Methionine and Metaphors. , 2014, , 21-43.		1
66	Randomized phase II pilot study of loratadine for the prevention of bone pain caused by pegfilgrastim.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9628-9628.	0.8	0
67	New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. <i>American Journal of Pathology</i> , 2013, 182, 1065-1077.	1.9	91
68	A Phase I Study of the Combination of Temozolomide with Irinotecan for Metastatic Sarcoma. <i>Cancers</i> , 2013, 5, 418-429.	1.7	8
69	Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. <i>British Journal of Cancer</i> , 2012, 106, 70-76.	2.9	17
70	Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. <i>Annals of Oncology</i> , 2012, 23, 785-790.	0.6	67
71	A Phase I Study of Concurrent External Beam Radiotherapy with Weekly Topotecan for Primary Treatment of Locally Advanced Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2012, 7, e44-e45.	0.5	0
72	Malignancies in Pregnancy 1. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 343-344.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Gynaecological cancers in pregnancy. <i>Lancet, The</i> , 2012, 379, 558-569.	6.3	377
74	Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. <i>Annals of Oncology</i> , 2012, 23, 3104-3110.	0.6	48
75	Topoisomerase 1 Inhibitors and Cancer Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 507-525.	0.9	41
76	DR6 as a Diagnostic and Predictive Biomarker in Adult Sarcoma. <i>PLoS ONE</i> , 2012, 7, e36525.	1.1	9
77	The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. <i>Cancer Management and Research</i> , 2012, 4, 1.	0.9	44
78	A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 547-554.	1.1	56
79	Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 437-444.	1.1	28
80	Cytotoxic activity of the titanium alkoxide (OPy) ₂ Ti(4AP) ₂ against cancer colony forming cells. <i>Investigational New Drugs</i> , 2012, 30, 114-120.	1.2	4
81	Epidermal growth factor receptor as a biomarker for cervical cancer. <i>Annals of Oncology</i> , 2011, 22, 2166-2178.	0.6	94
82	Systemic Management Strategies for Metastatic Soft Tissue Sarcoma. <i>Drugs</i> , 2011, 71, 2115-2129.	4.9	11
83	Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. <i>Journal of Cancer</i> , 2011, 2, 81-89.	1.2	43
84	Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1938-1945.	0.5	88
85	Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. <i>Melanoma Research</i> , 2011, 21, 76-79.	0.6	0
86	A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 393-397.	0.6	17
87	Locally advanced cervical cancer: what is the standard of care?. <i>Current Opinion in Oncology</i> , 2010, 22, 503-512.	1.1	33
88	GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 51-58.	1.1	69
89	Negotiating for Success: Navigating the Contracting Process for an Exemplary Research Program. <i>Journal of Oncology Practice</i> , 2010, 6, 107-110.	2.5	2
90	A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4513-4520.	0.8	44

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , 2010, 21, 1712-1717.	0.6	468
92	Breast Sarcomas. , 2010, , 555-579.		0
93	The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 231-241.	1.4	22
94	GPR30 predicts poor survival for ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 114, 465-471.	0.6	185
95	Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. <i>Gynecologic Oncology</i> , 2009, 114, 480-485.	0.6	42
96	Novel chemotherapy approaches for cervical cancer. <i>Cancer</i> , 2009, 115, 3166-3180.	2.0	73
97	Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2009, 27, 153-158.	1.2	1
98	A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 903-910.	1.1	48
99	Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 287-295.	1.1	30
100	9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 579.	2.2	5
101	Irinotecan Use During Pregnancy. <i>Obstetrics and Gynecology</i> , 2009, 114, 451-452.	1.2	34
102	Voreloxin. <i>Drugs of the Future</i> , 2009, 34, 363.	0.0	1
103	Abstract A184: A phase I study of 5-azacytidine (AZA) and erlotinib (E) for patients (pt) with advanced solid tumors. , 2009, , .		0
104	Abstract B212: QTc study of picoplatin with emphasis on pharmacodynamics of cardiac repolarization. , 2009, , .		0
105	Optimal modeling for phase I design of a two drug combination—results of a phase I study of cisplatin with 9-nitrocamptothecin. <i>Investigational New Drugs</i> , 2008, 26, 541-551.	1.2	4
106	Rate of Thromboembolic Events in Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2008, 85, 1032-1038.	0.7	14
107	Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 610-615.	0.8	4
108	Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3567-3572.	0.8	110

#	ARTICLE	IF	CITATIONS
109	Effects of radiotherapy and surgery for early breast cancer. <i>Lancet, The</i> , 2006, 367, 1654.	6.3	3
110	Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs. <i>Annals of the New York Academy of Sciences</i> , 2006, 922, 352-354.	1.8	42
111	A Phase II trial of oral capecitabine in patients with platinum " and taxane " refractory ovarian, fallopian tube, or peritoneal cancer. <i>Gynecologic Oncology</i> , 2006, 102, 468-474.	0.6	11
112	Incidence and Survival Rates for Female Malignant Germ Cell Tumors. <i>Obstetrics and Gynecology</i> , 2006, 107, 1075-1085.	1.2	303
113	Modeling the Effect of Tumor Size in Early Breast Cancer. <i>Annals of Surgery</i> , 2005, 241, 309-318.	2.1	67
114	Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 710-726.	1.2	53
115	A Potential Synergistic Anticancer Effect of Paclitaxel and Amifostine on Endometrial Cancer. <i>Cancer Research</i> , 2005, 65, 9517-9524.	0.4	29
116	Malignant Adnexal Masses in Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2005, 32, 569-593.	0.7	27
117	Alternative administration of camptothecin analogues. <i>Expert Opinion on Drug Delivery</i> , 2005, 2, 323-333.	2.4	13
118	Clinical Presentation and Natural History of Mesothelioma: Abdominal. , 2005, , 391-401.		4
119	Frequent Overexpression of STK15/Aurora-A/BTAK and Chromosomal Instability in Tumorigenic Cell Cultures Derived From Human Ovarian Cancer. <i>Oncology Research</i> , 2005, 15, 49-57.	0.6	38
120	Breast-Conserving Surgery With or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality. <i>Journal of the National Cancer Institute</i> , 2004, 96, 115-121.	3.0	353
121	Re: Breast-Conserving Surgery With or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1111-1112.	3.0	2
122	RESPONSE: Re: Breast-Conserving Surgery With or Without Radiotherapy: Pooled-Analysis for Risks of Ipsilateral Breast Tumor Recurrence and Mortality. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1255-1257.	3.0	4
123	Cyclin E deregulation alters the biologic properties of ovarian cancer cells. <i>Oncogene</i> , 2004, 23, 2648-2657.	2.6	58
124	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 1-7.	1.1	1
125	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 1-7.	1.1	16
126	Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 2319-2326.	3.2	168

#	ARTICLE	IF	CITATIONS
127	Ratios of involved nodes in early breast cancer. <i>Breast Cancer Research</i> , 2004, 6, R680-8.	2.2	141
128	Phase II clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Research and Clinical Oncology, 2003, 129, 549-555.	1.2	26
129	Phase II study of cetorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 552-559.	0.6	40
130	Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. <i>Proteomics</i> , 2003, 3, 1904-1911.	1.3	48
131	Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma. <i>Cancer Investigation</i> , 2003, 21, 682-689.	0.6	44
132	Diagnosis, Staging, and Surveillance of Cervical Carcinoma. <i>American Journal of Roentgenology</i> , 2003, 180, 1621-1631.	1.0	121
133	GnRH antagonists in the treatment of gynecological and breast cancers.. <i>Endocrine-Related Cancer</i> , 2003, 10, 291-299.	1.6	124
134	Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. <i>Clinical Cancer Research</i> , 2003, 9, 845-52.	3.2	44
135	Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. <i>Lancet, The</i> , 2002, 359, 2145-2152.	6.3	72
136	Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 202-207.	1.2	5
137	Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. <i>Supportive Care in Cancer</i> , 2002, 10, 573-578.	1.0	31
138	Irinotecan for the treatment of cervical cancer. <i>Oncology</i> , 2002, 16, 32-4.	0.4	9
139	Maturation of dendritic cells from ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 289-296.	1.1	6
140	Intracavitary therapies for mesothelioma. <i>Current Treatment Options in Oncology</i> , 2001, 2, 385-394.	1.3	2
141	Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 359-364.	1.2	154
142	Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. <i>Journal of Medical Virology</i> , 2001, 64, 195-198.	2.5	31
143	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. <i>Cancer</i> , 2001, 92, 2327-2333.	2.0	24
144	Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer. <i>Annals of Internal Medicine</i> , 2000, 132, 364.	2.0	149

#	ARTICLE	IF	CITATIONS
145	Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity. <i>Anti-Cancer Drugs</i> , 2000, 11, 565-568.	0.7	44
146	Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 83-88.	1.7	101
147	Docetaxel for Patients With Paclitaxel-Resistant Malignant Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2733-2739.	0.8	116
148	Alternative Administration of Camptothecin Analogues. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 237-246.	1.8	14
149	Phase I Study of 9-Nitrocamptothecin in Combination with Cisplatin for Patients with Advanced Malignancies. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 345-348.	1.8	5
150	Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 349-351.	1.8	4
151	Synchronous Primary Cancers of the Breast and Cervix: Planning Multidisciplinary Primary Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 99.	0.6	7
152	Fallopian Tube Carcinoma. , 2000, , 687-697.		0
153	Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 44-53.	1.2	10
154	Octreotide induced remission of a refractory small cell carcinoma of the endometrium. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 80-85.	1.2	15
155	TOPOISOMERASE-I INHIBITORS IN GYNECOLOGIC TUMORS. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 43-61.	0.9	5
156	PRESENT KNOWLEDGE OF GYNECOLOGIC SARCOMA MANAGEMENT. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 211-223.	0.9	1
157	THE ROLE OF MACROPHAGES IN ANTITUMOR DEFENSE OF PATIENTS WITH OVARIAN CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 135-144.	0.9	14
158	A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. <i>Anti-Cancer Drugs</i> , 1999, 10, 375-384.	0.7	58
159	Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. <i>Clinical and Experimental Immunology</i> , 1998, 112, 172-180.	1.1	34
160	Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470. <i>New England Journal of Medicine</i> , 1998, 338, 991-992.	13.9	123
161	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 1998, 9, 405-409.	0.7	11
162	Prolonged remission of endometrial cancer with paclitaxel and carboplatin. <i>Anti-Cancer Drugs</i> , 1998, 9, 283-286.	0.7	9

#	ARTICLE	IF	CITATIONS
163	Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor. <i>Anti-Cancer Drugs</i> , 1998, 9, 621-623.	0.7	4
164	A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. <i>Anti-Cancer Drugs</i> , 1998, 9, 36-44.	0.7	86
165	Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. <i>Anti-Cancer Drugs</i> , 1998, 9, 577.	0.7	5
166	A phase II trial of high-dose hydroxyurea administered parenterally in patients with epithelial ovarian carcinoma refractory to platinum. <i>International Journal of Gynecological Cancer</i> , 1998, 8, 494-498.	1.2	0
167	Invasive <i>Aspergillus</i> sinusitis During Bone Marrow Transplantation. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 436-438.	1.5	24
168	Taxanes in ovarian cancer treatment. <i>Current Opinion in Obstetrics and Gynecology</i> , 1997, 9, 14-20.	0.9	2
169	Complete Remission of Refractory Gestational Trophoblastic Disease with Brain Metastases Treated with Multicycle Ifosfamide, Carboplatin, and Etoposide (ICE) and Stem Cell Rescue. <i>Gynecologic Oncology</i> , 1997, 65, 366-369.	0.6	34
170	Paraneoplastic syndromes of gynecologic neoplasms.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1272-1282.	0.8	52
171	Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.. <i>Journal of Clinical Oncology</i> , 1997, 15, 625-631.	0.8	126
172	Phase I Clinical and Pharmacological Studies of 20-(S)-Camptothecin and 20-(S)-9-Nitrocamptothecin as Anticancer Agents. <i>Annals of the New York Academy of Sciences</i> , 1996, 803, 224-230.	1.8	62
173	Effects of interleukin-1 \pm on ovarian carcinoma in patients with recurrent disease. <i>European Journal of Cancer</i> , 1996, 32, 1609-1611.	1.3	17
174	Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1552-1557.	0.8	242
175	Frontiers of Ovarian Cancer Therapy. <i>Cancer Control</i> , 1996, 3, 137-144.	0.7	2
176	Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. <i>Anti-Cancer Drugs</i> , 1996, 7, 885-889.	0.7	5
177	Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon- $\hat{\pm}$ and 13-cis-retinoic acid. <i>Anti-Cancer Drugs</i> , 1996, 7, 800-804.	0.7	3
178	Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. <i>Anti-Cancer Drugs</i> , 1996, 7, 398-401.	0.7	17
179	Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. <i>Anti-Cancer Drugs</i> , 1996, 7, 503-506.	0.7	28
180	Recurrence of ovarian cancer as a delayed solitary parenchymal splenic metastasis. <i>International Journal of Gynecological Cancer</i> , 1996, 6, 496-498.	1.2	9

#	ARTICLE	IF	CITATIONS
181	The breakpoint cluster region site in patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. <i>Cancer</i> , 1995, 76, 992-997.	2.0	28
182	Section Review: Oncologic, Endocrine & Metabolic: Topoisomerase I inhibitors in gynaecologic cancers. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 1217-1232.	1.9	4
183	Subacute encephalopathic toxicity of cisplatin. <i>Lung Cancer</i> , 1995, 13, 305-309.	0.9	23
184	Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma. <i>European Journal of Cancer</i> , 1993, 29, 708-711.	1.3	8
185	Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the eortc malignant melanoma cooperative group. <i>Cancer</i> , 1988, 62, 1061-1065.	2.0	42